Replies to post #141873 on Biotech Values

[genisi]

Indeed the malignancies risk a real concern as it shows time-dependency pattern, but similar to what you've posted in #msg-75312624 I think RA docs want different drugs in the arsenal and they are familiar with immunosupressants side effects/risks and of course they will not put most patients on this drug.

[kamehameha]

initially starting with non-selective agents and then getting more selective

that's why the JAK3 inhibitor VX-509 is a good bet!